David Risinger
Stock Analyst
(4.77)
# 4,522
Out of 4,648 analysts
163
Total ratings
69.05%
Success rate
18.85%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $4.47 | +257.94% | 1 | Oct 24, 2024 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Market Perform | $1,175 → $1,077 | $828.84 | +29.94% | 7 | Sep 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $26.95 | +63.27% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $106.49 | +43.68% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $8.21 | +21.80% | 3 | Aug 6, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $49 | $41.87 | +17.03% | 1 | Jul 24, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.90 | +5.26% | 2 | Jul 9, 2024 | |
| ANAB AnaptysBio | Initiates: Outperform | $47 | $19.94 | +135.71% | 1 | Apr 16, 2024 | |
| AMGN Amgen | Upgrades: Outperform | $267 → $318 | $316.91 | +0.34% | 4 | Oct 11, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $6 → $11 | $15.89 | -30.77% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $66 | $55.45 | +19.03% | 3 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $806.14 | -43.19% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $58.47 | -28.17% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $135 → $153 | $200.47 | -23.68% | 6 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $472.80 | -22.80% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $89.84 | +1.29% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.76 | +72.91% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $194 → $186 | $158.24 | +17.54% | 2 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.53 | -13.27% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $16.97 | -41.07% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $16.92 | +118.68% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $109.41 | +60.86% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $11.45 | +39.74% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $25.41 | +77.10% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $9.26 | +277.97% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $12.56 | +226.43% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $175.18 | -0.67% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $27.20 | +87.50% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $18.64 | -57.08% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $101.87 | -12.63% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $8.41 | -64.33% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $26.59 | -39.83% | 9 | Apr 2, 2020 |
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $4.47
Upside: +257.94%
Regeneron Pharmaceuticals
Sep 24, 2024
Downgrades: Market Perform
Price Target: $1,175 → $1,077
Current: $828.84
Upside: +29.94%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $26.95
Upside: +63.27%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $106.49
Upside: +43.68%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $8.21
Upside: +21.80%
Tectonic Therapeutic
Jul 24, 2024
Initiates: Outperform
Price Target: $49
Current: $41.87
Upside: +17.03%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.90
Upside: +5.26%
AnaptysBio
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $19.94
Upside: +135.71%
Amgen
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $316.91
Upside: +0.34%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $15.89
Upside: -30.77%
Jul 10, 2023
Initiates: Market Perform
Price Target: $66
Current: $55.45
Upside: +19.03%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $806.14
Upside: -43.19%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $58.47
Upside: -28.17%
Feb 10, 2023
Upgrades: Market Perform
Price Target: $135 → $153
Current: $200.47
Upside: -23.68%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $472.80
Upside: -22.80%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $89.84
Upside: +1.29%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.76
Upside: +72.91%
Jan 20, 2023
Maintains: Outperform
Price Target: $194 → $186
Current: $158.24
Upside: +17.54%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.53
Upside: -13.27%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $16.97
Upside: -41.07%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $16.92
Upside: +118.68%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $109.41
Upside: +60.86%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $11.45
Upside: +39.74%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $25.41
Upside: +77.10%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $9.26
Upside: +277.97%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $12.56
Upside: +226.43%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $175.18
Upside: -0.67%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $27.20
Upside: +87.50%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $18.64
Upside: -57.08%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $101.87
Upside: -12.63%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $8.41
Upside: -64.33%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $26.59
Upside: -39.83%